Page last updated: 2024-11-07

aldosterone and Hepatorenal Syndrome

aldosterone has been researched along with Hepatorenal Syndrome in 9 studies

Hepatorenal Syndrome: Functional KIDNEY FAILURE in patients with liver disease, usually LIVER CIRRHOSIS or portal hypertension (HYPERTENSION, PORTAL), and in the absence of intrinsic renal disease or kidney abnormality. It is characterized by intense renal vasculature constriction, reduced renal blood flow, OLIGURIA, and sodium retention.

Research Excerpts

ExcerptRelevanceReference
" Midodrine and octreotide were dosed to obtain a stable increase of at least 15 mm Hg of mean arterial pressure."6.69Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. ( Amodio, P; Angeli, P; Caregaro, L; Craighero, R; Gatta, A; Gerunda, G; Maffei-Faccioli, A; Merenda, R; Roner, P; Sticca, A; Volpin, R, 1999)
"The adrenergic agonist midodrine improved circulatory and renal dysfunction when acutely administered in nonazotemic cirrhotic patients with ascites while its combination with octreotide has recently been proposed as an effective treatment of type 1 hepatorenal syndrome (HRS)."5.11The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. ( Al Bokharhii, J; Economou, M; Fotopoulos, A; Kalambokis, G; Katsaraki, A; Pappas, C; Tsianos, EV, 2005)
" Midodrine and octreotide were dosed to obtain a stable increase of at least 15 mm Hg of mean arterial pressure."2.69Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. ( Amodio, P; Angeli, P; Caregaro, L; Craighero, R; Gatta, A; Gerunda, G; Maffei-Faccioli, A; Merenda, R; Roner, P; Sticca, A; Volpin, R, 1999)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19901 (11.11)18.7374
1990's4 (44.44)18.2507
2000's3 (33.33)29.6817
2010's1 (11.11)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wong, F2
Raina, N1
Richardson, R1
Pantea, L1
Sniderman, K1
Kalambokis, G1
Economou, M1
Fotopoulos, A1
Al Bokharhii, J1
Pappas, C1
Katsaraki, A1
Tsianos, EV1
Green, J1
Better, OS1
Pasqualetti, P1
Festuccia, V1
Collacciani, A1
Di Lauro, G1
Casale, R1
Saló, J1
Fernández-Esparrach, G1
Ginès, P1
Ginès, A1
Guevara, M1
Sort, P1
Jiménez, W1
Arroyo, V1
Rivera, F1
Rodés, J1
Angeli, P1
Volpin, R1
Gerunda, G1
Craighero, R1
Roner, P1
Merenda, R1
Amodio, P1
Sticca, A1
Caregaro, L1
Maffei-Faccioli, A1
Gatta, A1
Knotek, M1
Rogachev, B1
Schrier, RW1
Fernandez-Seara, J1
Prieto, J1
Quiroga, J1
Zozaya, JM1
Cobos, MA1
Rodriguez-Eire, JL1
Garcia-Plaza, A1
Leal, J1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Midodrine and Albumin for Cirrhotic Patients in the Waiting List for Liver Transplantation[NCT00839358]Phase 4199 participants (Actual)Interventional2008-08-31Completed
Vasoconstrictors as Alternatives to Albumin After Large Volume Paracentesis in Cirrhosis[NCT00108355]Phase 429 participants (Actual)Interventional2003-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Development of Post-paracentesis Circulatory Dysfunction (PCD)

Defined as an increase in Plasma Renin Activity (PRA) by >50% from baseline to a level > 4 ng/mL/h at post-paracentesis day (NCT00108355)
Timeframe: 6 days after paracentesis

Interventionparticipants (Number)
Albumin (Control Group)2
Vasoconstrictor (Treatment Group)2

Time to Recurrence of Ascites.

Comparison between Albumin (Control group) and Vasoconstrictor (Treatment group) (NCT00108355)
Timeframe: Variable depending on the patient, average 10 days

Interventiondays (Median)
Albumin (Control Group)10
Vasoconstrictor (Treatment Group)8

Reviews

2 reviews available for aldosterone and Hepatorenal Syndrome

ArticleYear
Circulatory disturbance and renal dysfunction in liver disease and in obstructive jaundice.
    Israel journal of medical sciences, 1994, Volume: 30, Issue:1

    Topics: Adult; Aldosterone; Algorithms; Blood Circulation; Cholestasis; Diagnosis, Differential; Glomerular

1994
Update on peripheral arterial vasodilation, ascites and hepatorenal syndrome in cirrhosis.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2000, Volume: 14 Suppl D

    Topics: Aldosterone; Animals; Ascites; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Nitric Oxide; Peritoni

2000

Trials

3 trials available for aldosterone and Hepatorenal Syndrome

ArticleYear
Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
    Hepatology (Baltimore, Md.), 2004, Volume: 40, Issue:1

    Topics: Adrenergic alpha-Agonists; Albumins; Aldosterone; Ascites; Blood Volume; Creatinine; Drug Therapy, C

2004
The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:4

    Topics: Administration, Oral; Adrenergic alpha-Agonists; Adult; Aged; Aldosterone; Blood Flow Velocity; Drug

2005
Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
    Hepatology (Baltimore, Md.), 1999, Volume: 29, Issue:6

    Topics: Aldosterone; Ascites; Blood Pressure; Diuresis; Electrolytes; Gastrointestinal Agents; Glomerular Fi

1999

Other Studies

4 other studies available for aldosterone and Hepatorenal Syndrome

ArticleYear
Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment.
    Gut, 2010, Volume: 59, Issue:3

    Topics: Adult; Aged; Aldosterone; Female; Glomerular Filtration Rate; Hemodynamics; Hepatorenal Syndrome; Hu

2010
Circadian rhythms of plasma atriopeptin, plasma renin activity and plasma aldosterone in patients with hepatorenal syndrome.
    Life sciences, 1997, Volume: 60, Issue:4-5

    Topics: Aldosterone; Atrial Natriuretic Factor; Circadian Rhythm; Female; Hepatorenal Syndrome; Humans; Line

1997
Urinary endothelin-like immunoreactivity in patients with cirrhosis.
    Journal of hepatology, 1997, Volume: 27, Issue:5

    Topics: Adult; Aldosterone; Ascites; Atrial Natriuretic Factor; Endothelins; Female; Hepatorenal Syndrome; H

1997
Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure.
    Gastroenterology, 1989, Volume: 97, Issue:5

    Topics: Aldosterone; Female; Hemodynamics; Hepatorenal Syndrome; Humans; Kidney Diseases; Kidney Function Te

1989